



AMICUS THERAPEUTICS ANNOUNCES RETURN OF JOHN F. CROWLEY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Cranbury, NJ, March 5, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced that John F. Crowley has returned to his role as President and Chief Executive Officer of the company. Mr. Crowley recently completed a six-month active duty military obligation with the United States Navy. He is a commissioned officer in the Navy Reserve. Mr. Crowley took leave of absence starting September 11, 2006. During this period, Donald J. Hayden, Jr., Executive Chairman, served as Interim President and Chief Executive Officer. Mr. Hayden will continue in his role as Executive Chairman.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase 2 clinical trials for its two lead compounds, Amigal for Fabry disease, and AT2101 for Gaucher disease. The company is currently conducting Phase 1 trials with AT2220 for the treatment of Pompe disease.